Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 375 of 5804
-
Could a Patient's own blood and fat build a better breast after cancer surgery?
Disease control Recruiting nowThe goal of this clinical trial is to learn if a special type of fat graft, made by mixing a person's own fat with platelet-rich fibrin (PRF), works to fix breast shape defects after cancer surgery. PRF is a substance made from a person's own blood that is rich in growth factors,…
Phase: NA • Sponsor: The Leningrad Regional Clinical Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Two-Drug combo help young people with new type 1 diabetes keep making insulin?
Disease control Recruiting nowT cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG respo…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a milk thistle extract help fight brain cancer?
Disease control Recruiting nowMulticenter, double-blind, placebo-controlled, randomized trial. Patients affected by STAT3 positive newly diagnosed glioblastoma will be eligible. Patients are randomized using a stratified block randomization method with a 1:1 ratio in two arms: • Experimental/Control arm: Co…
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Hope for rare genetic disorder: new drug trial targets core symptoms
Disease control Recruiting nowThis Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.
Phase: PHASE3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New antibody drug takes aim at relapsed leukemia
Disease control Recruiting nowThe study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: experimental combo enters Late-Stage trial
Disease control Recruiting nowThe primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipirac…
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to shrink lung tumors
Disease control Recruiting nowEvaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat brain cancer
Disease control Recruiting nowThis clinical study aims to evaluate the tolerability, safety, and efficacy of Anbal-cel in patients with recurrent or refractory PCNSL or SCNSL. Subjects who have provided written consent and meet the inclusion and exclusion criteria through screening evaluations will undergo l…
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for hard-to-treat ovarian cancer: experimental drug targets key protein
Disease control Recruiting nowThis study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101…
Phase: PHASE1, PHASE2 • Sponsor: Joshua Palmer • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Self-Sampling could boost cervical cancer screening for women with HIV
Disease control Recruiting nowThe investigators propose to develop and/or adapt implementation strategies and a structured implementation plan to translate the HOPE intervention into existing healthcare practice in Ghana. These "implementation support strategies (ISS)" are implementation strategies relevant …
Phase: NA • Sponsor: Baylor University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could fewer chemo rounds plus a targeted drug beat standard care for older lymphoma patients?
Disease control Recruiting nowThe purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill combo aims to crush bad cholesterol
Disease control OngoingResearchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to outsmart Drug-Resistant cervical cancer
Disease control Recruiting nowThis Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Phase: PHASE2 • Sponsor: Precigen, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to boost cervical cancer treatment
Disease control Recruiting nowThis study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Ca…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New combo therapy aims to boost stroke recovery
Disease control Recruiting nowThis multicenter, prospective, double-blind, placebo-controlled, randomized trial (ANGEL-DRUG2) aims to evaluate the efficacy and safety of intravenous tirofiban following intravenous thrombolysis in patients with acute ischemic stroke who show insufficient neurological improveme…
Phase: PHASE4 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
MRI-Guided chemo reduction trial aims to spare TNBC patients from toxic drugs
Disease control Recruiting nowBreast cancer is the most common malignancy among women worldwide. Triple-negative breast cancer (TNBC), defined by the lack of estrogen receptor, progesterone receptor, and HER2 expression, comprises approximately 15% of all breast cancers and is the most aggressive subtype, ass…
Phase: PHASE2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New polio vaccine combo tested in infants: could speed up eradication
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to correspondin…
Phase: PHASE2 • Sponsor: PATH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC
-
New drug and high-tech scans aim to calm thyroid eye disease
Disease control Recruiting nowThis is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED). Eligible patients will receive Teprotumumab N01 and will be assessed using clinical and imaging parameters before and after treatment, with eac…
Phase: NA • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New immune-boosting combo targets stubborn lymphoma
Disease control Recruiting nowOpen Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC